Interim Report on the Safety and Efficacy of Longer-term Treatment with Nusinersen in Infantile-onset Spinal Muscular Atrophy (SMA): Updated Results from the SHINE Study

被引：0
|
作者：
Finkel, R.
Castro, D.
Farrar, M.
Tulinius, M.
Krosschell, K.
Saito, K.
Reyna, S.
Zhang, Y.
Bhan, I
Wong, J.
Farwell, W.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Neuromuscular Disorders; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
174
引用
收藏
页码：S122 / S123
页数：2
相关论文
共 50 条
  • [41] Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)
    Sajeev, G.
    Evans, R.
    Hawkins, N.
    Mahajan, A.
    Scott, D.
    Nam, J.
    Sutherland, S.
    Kokaliaris, C.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S164 - S164
  • [42] Safety and efficacy of nusinersen in infants/children with spinal muscular atrophy (SMA): part 1 of the phase 2 EMBRACE study
    Acsadi, G.
    Shieh, P.
    Crawford, T.
    Richardson, R.
    Natarajan, N.
    Castro, D.
    Gheuens, S.
    Gambino, G.
    Sun, P.
    Reyna, S.
    Farwell, W.
    Mueller-Felber, W.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S210 - S211
  • [43] Efficacy and safety of Nusinersen among children with spinal muscular atrophy from North India: A prospective cohort study (NICE-SMA study)
    Pandey, Abhishek
    Suthar, Renu
    Sirari, Titiksha
    Malviya, Manisha
    Saxena, Somya
    Yaddanapudi, Sandhya
    Garg, Shobit
    Saini, Arushi G.
    Sahu, Jitendra K.
    Sankhyan, Naveen
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2025, 54 : 42 - 49
  • [44] Nusinersen experience in teenagers and young adults with spinal muscular atrophy (SMA): Results from CS2/CS12 and SHINE
    Deconinck, N.
    Darras, B. T.
    Day, J. W.
    Chiriboga, C. A.
    Iannaccone, S. T.
    Swoboda, K. J.
    Finkel, R. S.
    Tulinius, M.
    Saito, K.
    Montes, J.
    Mignon, L.
    Sun, P.
    Bhan, I.
    Gheuens, S.
    Bevernage, S. P.
    Farwell, W.
    De Vivo, D. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 143 - 144
  • [45] LONGITUDINAL TRENDS IN HOSPITALIZATION RATES IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (SMA) TREATED WITH NUSINERSEN UP TO 4.5 YEARS: RESULTS FROM THE CHERISH AND SHINE STUDIES
    Jiang, T.
    Darras, B.
    Youn, B.
    Makepeace, C.
    Chin, R.
    Berger, Z.
    Raynaud, S.
    Paradis, A. D.
    Johnson, N.
    VALUE IN HEALTH, 2023, 26 (06) : S34 - S35
  • [46] Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan
    Tachibana, Yosuke
    Sato, Ryusuke
    Makioka, Haruki
    Hoshino, Misuzu
    Jin, Mingshou
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (11) : 1185 - 1197
  • [47] Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with Spinal Muscular Atrophy (SMA) Treated With Nusinersen After Onasemnogene Abeparvovec
    Kuntz, Nancy
    Parsons, Julie
    Brandsema, John F.
    Proud, Crystal
    Finkel, Richard
    Swoboda, Kathryn
    Masson, Ricardo
    Liu, Yingying
    Makepeace, Corinne
    Paradis, Angela
    Berger, Zdenek
    Somera-Molina, Kathleen
    NEUROLOGY, 2023, 100 (17)
  • [48] Nusinersen demonstrates greater efficacy in infants with shorter disease duration: End of study results from the ENDEAR study in infants with spinal muscular atrophy (SMA)
    Servais, L.
    Farrar, M.
    Finkel, R.
    Kirschner, J.
    Muntoni, F.
    Sun, P.
    Gheuens, S.
    Schneider, E.
    Farwell, W.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S211 - S211
  • [49] Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy: interim results from the phase 2 NURTURE study
    Ryan, M.
    De Vivo, D.
    Bertini, E.
    Hwu, W.
    Crawford, T.
    Swoboda, K.
    Finkel, R.
    Kirschner, J.
    Kuntz, N.
    Parsons, J.
    Butterfield, R.
    Topaloglu, H.
    Ben Omran, T.
    Sansone, V.
    Jong, Y.
    Shu, F.
    Foster, R.
    Bhan, I.
    Fradette, S.
    Farwell, W.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S185 - S185
  • [50] Nusinersen in Infants who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy: Interim Results from the Phase 2 NURTURE Study
    Butterfield, R.
    De Vivo, D.
    Bertini, E.
    Hwu, W-L
    Crawford, T.
    Swoboda, K.
    Finkel, R.
    Kirschner, J.
    Kuntz, N.
    Parsons, J.
    Ryan, M.
    Topaloglu, H.
    Ben Omran, T.
    Sansone, V
    Jong, Y-J
    Shu, F.
    Johnson, K.
    Foster, R.
    Bhan, I
    Fradette, S.
    Farwell, W.
    ANNALS OF NEUROLOGY, 2019, 86 : S117 - S117
12345